BioSpace News Archive

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the Premarket Approval (PMA) supplement application to extend the wearable li

Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders. Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigatio

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

PetVivo Holdings, Inc. an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce the certification and opening of its new medical device manufacturing facility and Center of Excellence in Edina, Minnesota.

BioLife Sciences Inc. (OTC Markets: BLFE) is introducing non-contact human temperature screening to its lineup of products designed to provide businesses with cost-effective solutions to successfully navigate through the current health crisis. BioLife Sciences’ non-contact human temperature screening technology offers state-of-the-art, intelligent thermal imaging technology. The AI Screening Technology can measure temperature and

The global portable medical devices market is witnessing a notable increase in its growth statistics and that will also be the case for the period of 2020 to 2030.

Photocure ASA announces that the European Patent Office has granted patent EP 2983780 covering the commercial Cevira® device in Europe until 2034.

Medivir AB announced it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020.

MindMed To Provide Funding for Psychedelic Medicine Research Training Program at NYU Langone Health and NYU Grossman School of Medicine

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the Company will release third quarter 2020 operating results after the close of the market on Monday, November 9, 2020.